



# Annual Report 2019 Investor Presentation

31 March, 2020



Oncology Venture

# Agenda

---

- COVID-19 (Steve Carchedi)
- General Business Update (Steve Carchedi)
- 2019 Financial Highlights (Henrik Moltke)
- Q&A



# Disclaimer

This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward-looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Oncology Venture does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.



# COVID-19

## Key takeaways

- We comply with national guidelines
- Most employees work from home
- No delay in our internal operations
- Delay may occur at clinical trial sites



# Strategic Realignment and Execution

Key takeaways

- New Executive Management team
- New Strategy
  - Commercialization
  - Dovitinib
  - 2X-121
  - IXEMPRA®
- Dovitinib
  - Guidance received from the FDA
  - Focus on non-inferiority to Sorafenib/Nexavar®
  - Accompanying DRP® application will be filed separately

**Dovitinib**

**IXEMPRA®**

**2X - 121**



Oncology Venture

# 2019 Financial Highlights

Key takeaways

- 100 million SEK share issue
- Introduced robust financial controls
- Across-the-board cost reductions
- Year ended with balance sheet without debt
  
- Today's new financing deal: Convertible loan of up to 100 million SEK, solely to be decided by OV



Oncology Venture

# New Financing

## Key Takeaways

- Up to 100 mill. In 10 tranches in 24 months
- Flexible – from 0 – 100 mill SEK
- Conversion price at 95 %
- Coupon rate: 0 %
- No warrants
- No 'share lending'
- We are in full control





# Q&A Session

---